Livagen

peptide · headlineResearch use only

Regulates gene expression in thymic and immune-related tissues

Summary

Livagen is a thymic-derived short peptide with powerful gene-regulatory effects. It stabilizes chromatin, promotes DNA repair, and enhances immune signaling, particularly in aging individuals. It is studied for its epigenetic role in longevity and tissue regeneration.

How it works

Regulates gene expression in thymic and immune-related tissues
Stabilizes DNA structure and chromatin remodeling in aging cells
Supports epigenetic regulation of nuclear protein synthesis
Stimulates thymus-derived immune functions

Dosing

unit: mcg
low dose: 5
frequency: Daily
high dose: 20
standard dose: 10
administration route: Subcutaneous (SQ)

Cycling

Inject daily for 20–30 days. Repeat every 6–12 months depending on aging or immune protocols.

Side effects

common: ["Mild digestive issues, slight headaches (user-reported)"]

long term: ["Very limited safety data in humans"]

Chemistry & PK

sequence: Ala-Glu-Asp-Gly

half life: Approximately 4 hours

degradation: Metabolized via liver and renal peptidases

molecular weight: 467.57

molecular formula: C23H37N5O6

tissue specificity: Targets thymus, immune tissues, and nuclei of aging cells

Verified citations

2 · PubMed-checked

Effects of Livagen peptide on chromatin activation in lymphocytes from old people.mechanismPMID 12533768 ↗
Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract.preclinicalPMID 16075683 ↗

Used for

No condition evidence rows yet.

Legal / compounding

Research use only

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.